Lexaria Bioscience Corp. (LEXX)
| Market Cap | 4.76M -74.4% |
| Revenue (ttm) | 194,000 -68.5% |
| Net Income | -7.73M |
| EPS | -5.14 |
| Shares Out | 1.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,134 |
| Open | 3.180 |
| Previous Close | 3.090 |
| Day's Range | 2.800 - 3.240 |
| 52-Week Range | 2.800 - 21.600 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 13, 2026 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including ... [Read more]
Financial Performance
In fiscal year 2025, Lexaria Bioscience's revenue was $705,923, an increase of 52.05% compared to the previous year's $464,278. Losses were -$11.90 million, 105.4% more than in 2024.
Financial StatementsNews
Lexaria Bioscience Registration statement: Registration filing
Lexaria Bioscience filed a registration statement on October 2, 2026, providing details about a securities offering with the SEC.
Lexaria Bioscience files to sell 923,827 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 923,827 shares of common stock. The company is not selling any…
Lexaria Bioscience updates financial position
Lexaria Bioscience (LEXX) said it is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at $12.92/share. The combined net p...
Lexaria Updates Financial Position
Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the follo...
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previ...
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously anno...
Lexaria Bioscience announces exercise of warrants for $5.9M in proceeds
Lexaria Bioscience (LEXX)s announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common ...
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced th...
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announce...
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will part...
Lexaria Bioscience receives $2.6M tax rebate payment
Lexaria Bioscience (LEXX) has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria’s wholly-owned Australian subsidiary ...
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), ...
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation incr...
Lexaria Bioscience enters MTA with PegBio
Lexaria Bioscience (LEXX) announces that it has entered into a Material Transfer Agreement, MTA, with Pegbio to investigate Lexaria’s DehydraTECH technology with a proprietary PegBio molecule under de...
Lexaria Enters a Material Transfer Agreement With PegBio
KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into...
Lexaria Enters a Material Transfer Agreement with PegBio
Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it h...
Lexaria Bioscience Corp trading resumes
10:04 EDT Lexaria Bioscience (LEXX) Corp trading resumes
Lexaria Bioscience Corp trading halted, volatility trading pause
09:59 EDT Lexaria Bioscience (LEXX) Corp trading halted, volatility trading pause
Lexaria Bioscience Corp trading halted, news pending
19:50 EDT Lexaria Bioscience (LEXX) Corp trading halted, news pending
Lexaria Bioscience announces effective date for reverse stock split
Lexaria Bioscience (LEXX) intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026. The primary goal of the Reverse…
Lexaria Announces Effective Date for Reverse Stock Split
KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect ...
Lexaria Bioscience Quarterly report: Q3 2026
Lexaria Bioscience has published its Q3 2026 quarterly earnings report on July 13, 2026.
Lexaria Updates Business Development
Kelowna, British Columbia – July 6, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to have exp...
Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing
Lexaria Bioscience (LEXX) announces that dosing began on schedule on June 14th with Human Pilot Study #7, GLP-1-H26-7, that is evaluating two oral DehydraTECH-semaglutide compositions against Novo Nor...
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that dosing...